Novel Bone Morphogenetic Protein-6 Biocompatible Carrier Device for Bone Regeneration
We propose a regenerative medicine clinical trial of the therapeutic system OSTEOGROW for regenerating bone through harnessing a novel bone device to accelerate and enhance bone repair.
The osteogenic device is composed of an autologous carrier and a biologically active recombinant human protein offering a therapeutic solution in bone regeneration superior to currently available options. The autologous carrier is a whole blood-derived coagulum device (WBCD) from the peripheral blood of a patient, which will act as an endogenous biocompatible material causing significantly less inflammatory reactions than currently used bone devices.
The bone inducing molecule is the recombinant human bone morphogenetic protein-6 (BMP6) which binds to WBCD and is more potent than other BMPs in stimulating bone formation in preclinical animal models. The consortium members will scale-up the production of BMP6 from an already developed working cell bank to enter clinical trials on bone regeneration.
The bone diseases we will treat locally with OSTEOGROW are acute radius fractures and bone defects of the tibia. These conditions are widespread and highly debilitating diseases for which such therapy holds great promise. The Department of Orthopaedics of the Medical University of Vienna will be resposible for the conduction of the clincial trial.
MedUni Vienna Researchers
The MedUni Vienna is project partner under the leadership of Univ.Prof.Dr.Reinhard Windhager, Department of Orthopedics.
ao.Univ. Prof.in Dr.in Catharina Chiari (Subinvestigator)
Project coordinator: Prof. Slobodan Vukicevic / University of Zagreb School of Medicine
Project partners: 11
|Topic||FP7-HEALTH-2011-two-stage / Small/medium-scale focused research project|
|Project Duration||01.01.12 bis 30.06.2016|
|Funding Volume, total||5.683.089,30 €|
|Funding Volume, Medicin University of Vienna||599.400 €|